involved charging other healthcare software companies to use Redox’s data-integration tools.
—Janesville-based Shine Medical Technologies raised nearly $6.9 million in debt financing from 26 investors, according to a document filed with federal securities regulators. Shine is seeking to resume domestic manufacturing of an isotope that is in turn used to produce technetium-99m, the most widely used radioisotope in medical diagnostic imaging. The company recently broke ground on an 11,500-square-foot prototype production facility, where it will test its particle accelerator-based technology for producing isotopes.
—The Milwaukee-based pharmacogenetics startup Right Patient Right Drug (RPRD) Diagnostics announced a collaboration with Orient Bio, a biotech company based in South Korea. RPRD is developing technology to examine how patients’ genetic profiles affect their likelihood of reacting to particular drugs. The startup said in a press release that Orient Bio is particularly interested in a panel developed by RPRD that’s highly relevant for patients of East Asian ethnicity who may receive thiopurine drug treatment, prescribed for patients with leukemia and other diseases.
